Kyle Faget Authors Article on Clinical Trial Agreement Considerations for Pharmaceutical Sponsors
January 13, 2022
Foley & Lardner LLP Partner Kyle Faget authored an article, “Clinical Trial Agreement Considerations for Pharmaceutical Sponsors,” for LexisNexis Practical Guidance. The article provides guidance on key provisions when negotiating clinical trial agreements (CTAs) on behalf of pharmaceutical companies.
Faget, co-chair of Foley’s Health Care and Life Sciences Practice Groups, covers topics such as the role of contract research organizations (CROs) in CTA negotiations, preamble, confidentiality, intellectual property, indemnification, subject injury, limitation on liability, and publication rights.
Author(s)
Related Insights
July 7, 2025
Labor & Employment Law Perspectives
Florida Bucks Trend, Enacts New Employer-Friendly Noncompete Statute
While the recent trend across the country has been to restrict noncompete agreements, Florida has just made it easier for employers to…
July 7, 2025
Health Care Law Today
DOJ-HHS False Claims Act Working Group: Focus on Medicare Payment Suspensions
In a July 2, 2025, press release, the U.S. Department of Justice (DOJ) announced a new “DOJ-HHS False Claims Act Working Group” (the…
July 2, 2025
Energy Current
Has SCOTUS Pre-decided Whether the NRC Can License Private Off-Site High-Level Nuclear Waste Storage Facilities?
On June 18, 2025, the U.S. Supreme Court, in NRC v. Texas, issued an opinion holding that the State of Texas did not have standing to…